Shares of Ocera Therapeutics, Inc. (NASDAQ:OCRX) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $3.85.

Several brokerages have recently weighed in on OCRX. Aegis reissued a “buy” rating and issued a $3.00 price target on shares of Ocera Therapeutics in a research note on Monday, April 17th. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Finally, Zacks Investment Research cut Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 17th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC acquired a new stake in shares of Ocera Therapeutics during the first quarter worth approximately $2,817,000. Hikari Power Ltd acquired a new stake in shares of Ocera Therapeutics during the first quarter worth approximately $328,000. Finally, Renaissance Technologies LLC increased its stake in Ocera Therapeutics by 17.9% in the fourth quarter. Renaissance Technologies LLC now owns 219,100 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 33,300 shares in the last quarter. Institutional investors own 20.85% of the company’s stock.

Ocera Therapeutics (OCRX) opened at 1.10 on Tuesday. The company’s market cap is $29.16 million. The stock’s 50 day moving average is $1.13 and its 200 day moving average is $1.15. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $3.15.

Ocera Therapeutics (NASDAQ:OCRX) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative return on equity of 175.02% and a negative net margin of 4,416.26%. On average, analysts predict that Ocera Therapeutics will post ($1.08) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/09/ocera-therapeutics-inc-nasdaqocrx-receives-4-50-consensus-price-target-from-analysts-updated-updated-updated.html.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Analyst Recommendations for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Stock Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related stocks with our FREE daily email newsletter.